These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 6585590

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
    van Acker SA, Voest EE, Beems DB, Madhuizen HT, de Jong J, Bast A, van der Vijgh WJ.
    Cancer Res; 1993 Oct 01; 53(19):4603-7. PubMed ID: 8402634
    [Abstract] [Full Text] [Related]

  • 43. Toxicology and Carcinogenesis Studies of C.I. Pigment Red 3 (CAS No. 2425-85-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1992 Mar 01; 407():1-289. PubMed ID: 12621523
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, van der Vijgh WJ.
    Clin Cancer Res; 1997 Oct 01; 3(10):1747-54. PubMed ID: 9815559
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
    Li W, Xu B, Xu J, Wu XL.
    Basic Clin Pharmacol Toxicol; 2009 Mar 01; 104(3):192-7. PubMed ID: 19143757
    [Abstract] [Full Text] [Related]

  • 49. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
    Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB.
    Cancer Chemother Pharmacol; 2004 Feb 01; 53(2):141-50. PubMed ID: 14564477
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE, Asker ME, Ali SI, el-Fattah TM.
    J Pharm Pharmacol; 2004 Jun 01; 56(6):757-68. PubMed ID: 15231041
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats.
    Lahouel M, Viotte G, Sumereau E, Morin JP, Fillastre JP.
    Drugs Exp Clin Res; 1987 Jun 01; 13(10):593-9. PubMed ID: 3428123
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.